Cancer Research and Treatment

Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors

Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang

Molecular Analysis of Biliary Tract Cancers with the Custom 3′ RACE-Based NGS Panel

Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, Natalia A. Bordovskaya, Anna D. Shestakova, Aleksandr S. Martianov, Mikhail G. Bubnov, Anna S. Shishkina, Maria V. Semina, Aleksandr A. Romanko, Ekaterina S. Kuligina, Evgeny N. Imyanito

ROS1-dependent cancers — biology, diagnostics and therapeutics

Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A. Davare

Nature Reviews Clinical Oncology.2021; 18(1): 35. CrossRef

A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors

Christos Fountzilas, Alex Adjei, Mateusz Opyrchal, Rachel Evans, Mohammad Ghasemi, Kristopher Attwood, Adrienne Groman, Wiam Bshara, Andrew Goey, John Wilton, Wen Wee Ma, Renuka Iyer

International Journal of Cancer.2021; 149(12): 2063. CrossRef

Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository

Divya A. Parikh, Guneet Walia, Janet Freeman-Daily, Merel Hennink, Tori Tomalia, Lysa Buonanno, Lisa Goldman, Bonnie Addario, Manali I. Patel

JCO Oncology Practice.2020; 16(2): e183. CrossRef

Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas

Jeremy Augustin, Caroline Gabignon, Aurélie Scriva, Laëtitia Menu, Claire Calmel, Olivier Scatton, François Paye, Jean-François Fléjou, Françoise Praz, Pascale Cervera, Dominique Wendum

Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma

Christopher D. Jakubowski, Aditya A. Mohan, Ihab R. Kamel, Mark Yarchoan

Emerging pathways for precision medicine in management of cholangiocarcinoma

Amir A. Rahnemai-Azar, Arezou Abbasi, Alexandra W. Acher, Sharon M. Weber, Timothy M. Pawlik

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Se-Hoon Lee, Boram Lee, Joon Ho Shim, Kwang Woo Lee, Jae Won Yun, Sook-Young Kim, Tae-You Kim, Yeul Hong Kim, Young Hyeh Ko, Hyun Cheol Chung, Chang Sik Yu, Jeeyun Lee, Sun Young Rha, Tae Won Kim, Kyung Hae Jung, Seock-Ah Im, Hyeong-Gon Moon, Sukki Cho, J

Cancer Research and Treatment.2019; 51(1): 211. CrossRef

Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review

B. N. Gurmikov, Yu. A. Kovalenko, V. A. Vishnevsky, A. V. Chzhao

Advances in molecular oncology.2019; 6(1): 37. CrossRef

Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives

Roberto Filippi, Pasquale Lombardi, Virginia Quarà, Elisabetta Fenocchio, Giacomo Aimar, Michela Milanesio, Francesco Leone, Massimo Aglietta

Expert Opinion on Pharmacotherapy.2019; 20(17): 2121. CrossRef

Intrahepatic cholangiocarcinoma: current management and emerging therapies

Amir A. Rahnemai-Azar, Allison B. Weisbrod, Mary Dillhoff, Carl Schmidt, Timothy M. Pawlik

Expert Review of Gastroenterology & Hepatology.2017; 11(5): 439. CrossRef

Journal of Clinical Pathology.2017; 70(12): 1001. CrossRef